Difference between revisions of "Vosaroxin (SNS-595)"
m |
|||
| Line 12: | Line 12: | ||
# Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE. A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2014 Nov 7. [Epub ahead of print] [http://www.ncbi.nlm.nih.gov/pubmed/25381131 PubMed] | # Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE. A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2014 Nov 7. [Epub ahead of print] [http://www.ncbi.nlm.nih.gov/pubmed/25381131 PubMed] | ||
# Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2014 Nov 17. [Epub ahead of print] [http://www.ncbi.nlm.nih.gov/pubmed/25403830 PubMed] | # Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2014 Nov 17. [Epub ahead of print] [http://www.ncbi.nlm.nih.gov/pubmed/25403830 PubMed] | ||
| + | # Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015 May 7;125(19):2923-32. Epub 2015 Mar 24. [http://www.ncbi.nlm.nih.gov/pubmed/25805811 PubMed] | ||
==Clinical trials== | ==Clinical trials== | ||
Revision as of 14:45, 26 June 2015
in clinical trials
General information
Class/mechanism: Anticancer quinolone derivative (AQD). Vosaroxin intercalates DNA and inhibits topoisomerase II activity, which results in site-specific double-strand DNA breaks, G2 arrest in the cell cycle, and apoptosis. It is hypothesized that it may not be vulnerable to certain mechanisms of resistance since it is not a P-glycoprotein (P-gp) substrate. The vosaroxin naphthyridine core is believed to be less chemically promiscuous and to generate fewer reactive oxygen species (ROS), which could decrease the risk of cardiotoxicity. Its activity is independent of the p53 family.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Preliminary data
Acute myeloid leukemia
- Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE. A phase 1b/2 study of combination vosaroxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 2014 Nov 7. [Epub ahead of print] PubMed
- Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. Br J Haematol. 2014 Nov 17. [Epub ahead of print] PubMed
- Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. Blood. 2015 May 7;125(19):2923-32. Epub 2015 Mar 24. PubMed
Clinical trials
- Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
- Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
- Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
- Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)
Patient drug information
No information available.
Also known as
SNS-595, Voreloxin.